Presentation is loading. Please wait.

Presentation is loading. Please wait.

Evaluation of different add-back estradiol and progesterone treatments to gonadotropin- releasing hormone agonist treatment in patients with premenstrual.

Published byRandolf Francis Modified over 6 years ago

Similar presentations

Presentation on theme: "Evaluation of different add-back estradiol and progesterone treatments to gonadotropin- releasing hormone agonist treatment in patients with premenstrual."— Presentation transcript:

1 Evaluation of different add-back estradiol and progesterone treatments to gonadotropin- releasing hormone agonist treatment in patients with premenstrual dysphoric disorder  Birgitta Segebladh, MD, Anna Borgström, MSc, Sigrid Nyberg, PhD, Marie Bixo, MD, PhD, Inger Sundström-Poromaa, MD, PhD  American Journal of Obstetrics & Gynecology  Volume 201, Issue 2, Pages 139.e1-139.e8 (August 2009) DOI: /j.ajog Copyright © 2009 Mosby, Inc. Terms and Conditions

2 FIGURE 1 Flow-chart of the study
PMDD, premenstrual dysphoric disorder. Segebladh. Evaluation of add-back treatments for patients with PMDD. Am J Obstet Gynecol 2009. American Journal of Obstetrics & Gynecology  , 139.e1-139.e8DOI: ( /j.ajog ) Copyright © 2009 Mosby, Inc. Terms and Conditions

3 FIGURE 2 Schematic diagram of the study design
GnRH, gonadotropin-releasing hormone; HRT, hormone replacement therapy. Segebladh. Evaluation of add-back treatments for patients with PMDD. Am J Obstet Gynecol 2009. American Journal of Obstetrics & Gynecology  , 139.e1-139.e8DOI: ( /j.ajog ) Copyright © 2009 Mosby, Inc. Terms and Conditions

4 FIGURE 3 Negative mood during add-back hormone replacement therapy to GnRH agonist Mean ± SEM daily symptom ratings on a 9-point cyclicity diagnoser (CD) scale of irritability, anxiety, depressed moods, and impact on daily life during the last 10 days of each treatment cycle in 27 patients with PMDD. Treatments consisted of leuprolide acetate only, leuprolide acetate with add-back of 1.5E2P, 0.5E2P, and 1.5E2-only, respectively. During the first treatment cycle, the 2-way analysis of variance revealed significant differences between the add-back hormone replacement therapy regimens (premenstrual irritability scores, F[3,26] = 5.69 [P < .001]; anxiety scores, F[3,26] = 4.50; [P < .01]; depression, F[3,26] = 6.00 [P < .001]; mood swings, F[3,26] = 3.72 [P < .05]; and impact on daily life scores, [F3,26] = 3.64 [P < .05]). Post-hoc analyses are given in the Figure. Triple asterisks denote P < .001, Tukey Honestly Significance Test. GnRH, gonadotropin-releasing hormone. Segebladh. Evaluation of add-back treatments for patients with PMDD. Am J Obstet Gynecol 2009. American Journal of Obstetrics & Gynecology  , 139.e1-139.e8DOI: ( /j.ajog ) Copyright © 2009 Mosby, Inc. Terms and Conditions

5 FIGURE 4 Cross-over effects that depended on the first used add-back treatment Summarized negative mood symptoms throughout the study course, depending on with which treatment the subjects started. Each point represents the group mean ± SEM of the last 10 days of each treatment cycle. Patients with premenstrual dysphoric disorder who started with 1.5E2P continued to display higher negative mood ratings throughout the study, compared with subjects who started with 1.5E2-only (F[2,26] = 5.73; P < .01). During the gonadotropin-releasing hormone (GnRH) cycle, there was no difference between groups in summarized negative mood symptoms. CD, cyclicity diagnoser. Segebladh. Evaluation of add-back treatments for patients with PMDD. Am J Obstet Gynecol 2009. American Journal of Obstetrics & Gynecology  , 139.e1-139.e8DOI: ( /j.ajog ) Copyright © 2009 Mosby, Inc. Terms and Conditions

6 FIGURE 5 Physical symptoms during add-back hormone replacement therapy to GnRH agonist Mean ± SEM daily symptom ratings on a 9-point cyclicity diagnoser (CD) scale of bloating and breast tenderness during the last 10 days of each treatment cycle in 27 patients with premenstrual dysphoric disorder. Treatments consisted of leuprolide acetate only, leuprolide acetate with add-back of 1.5E2P, 0.5E2P, and 1.5E2-only, respectively. The 2-way analysis of variance revealed significant differences between add-back hormone replacement therapy regimens in breast tenderness (F[3,26] = 7.67; P < .001) and bloating (F[3,26] = 13.30; P < .001). Post-hoc analyses are given. The single asterisk denotes P < .05, Tukey Honestly Significance Test; the triple asterisks denote P < .001, Tukey Honestly Significance Test. GnRH, gonadotropin-releasing hormone. Segebladh. Evaluation of add-back treatments for patients with PMDD. Am J Obstet Gynecol 2009. American Journal of Obstetrics & Gynecology  , 139.e1-139.e8DOI: ( /j.ajog ) Copyright © 2009 Mosby, Inc. Terms and Conditions

Download ppt "Evaluation of different add-back estradiol and progesterone treatments to gonadotropin- releasing hormone agonist treatment in patients with premenstrual."

Similar presentations

Use of other treatments before hysterectomy for benign conditions in a statewide hospital collaborative Lauren E. Corona, BS, Carolyn W. Swenson, MD, Kyle.

Use of other treatments before hysterectomy for benign conditions in a statewide hospital collaborative Lauren E. Corona, BS, Carolyn W. Swenson, MD, Kyle.
Use of metformin in polycystic ovary syndrome Ruchi Mathur, MD, Carolyn J. Alexander, MD, Jacqueline Yano, MA, Bradley Trivax, MD, Ricardo Azziz, MD, MPH,

Use of metformin in polycystic ovary syndrome Ruchi Mathur, MD, Carolyn J. Alexander, MD, Jacqueline Yano, MA, Bradley Trivax, MD, Ricardo Azziz, MD, MPH,
First pregnancies, live birth, and in vitro fertilization outcomes after transplantation of frozen-banked ovarian tissue with a human extracellular matrix.

First pregnancies, live birth, and in vitro fertilization outcomes after transplantation of frozen-banked ovarian tissue with a human extracellular matrix.
Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18 Mary.

Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18 Mary.
Management of severe anemia secondary to menorrhagia in a Jehovah's Witness: a case report and treatment algorithm  Griselda Gutierrez, MD, FACOG, Joy.

Management of severe anemia secondary to menorrhagia in a Jehovah's Witness: a case report and treatment algorithm  Griselda Gutierrez, MD, FACOG, Joy.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 5-year outcome from the randomized EMMY trial  Sanne M.

Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 5-year outcome from the randomized EMMY trial  Sanne M.
Relationship between the time interval from antenatal corticosteroid administration until preterm birth and the occurrence of respiratory morbidity  Femke.

Relationship between the time interval from antenatal corticosteroid administration until preterm birth and the occurrence of respiratory morbidity  Femke.
Prevalence and factors associated with coinfection of human papillomavirus and Chlamydia trachomatis in adolescents and young women  Dejan R. Nonato,

Prevalence and factors associated with coinfection of human papillomavirus and Chlamydia trachomatis in adolescents and young women  Dejan R. Nonato,
Changes in rates of hysterectomy and uterine conserving procedures for treatment of uterine leiomyoma  Gavin F. Jacobson, MD, Ruth E. Shaber, MD, Mary.

Changes in rates of hysterectomy and uterine conserving procedures for treatment of uterine leiomyoma  Gavin F. Jacobson, MD, Ruth E. Shaber, MD, Mary.
Katherine Gabriel-Cox, MD, Gavin F

Katherine Gabriel-Cox, MD, Gavin F
Auricular acupuncture as a treatment for pregnant women who have low back and posterior pelvic pain: a pilot study  Shu-Ming Wang, MD, Peggy DeZinno,

Auricular acupuncture as a treatment for pregnant women who have low back and posterior pelvic pain: a pilot study  Shu-Ming Wang, MD, Peggy DeZinno,
Laura M. Glaser, MD, Farah A. Alvi, MD, MS, Magdy P. Milad, MD, MS 

Laura M. Glaser, MD, Farah A. Alvi, MD, MS, Magdy P. Milad, MD, MS 
Meloxicam effectively inhibits preterm labor uterine contractions in a chronically catheterized pregnant sheep model: Impact on fetal blood flow and fetal-maternal.

Meloxicam effectively inhibits preterm labor uterine contractions in a chronically catheterized pregnant sheep model: Impact on fetal blood flow and fetal-maternal.
Irritable Mood as a Symptom of Depression in Youth: Prevalence, Developmental, and Clinical Correlates in the Great Smoky Mountains Study  Argyris Stringaris,

Irritable Mood as a Symptom of Depression in Youth: Prevalence, Developmental, and Clinical Correlates in the Great Smoky Mountains Study  Argyris Stringaris,
Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study  Wang Ya, MD, Cheryl Reifer,

Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study  Wang Ya, MD, Cheryl Reifer,
Preeclampsia in healthy women and endothelial dysfunction 10 years later  Miriam Kristine Sandvik, MD, PhD, Elisabeth Leirgul, MD, Ottar Nygård, MD, PhD,

Preeclampsia in healthy women and endothelial dysfunction 10 years later  Miriam Kristine Sandvik, MD, PhD, Elisabeth Leirgul, MD, Ottar Nygård, MD, PhD,
Michael P. Diamond, MD, Richard S

Michael P. Diamond, MD, Richard S
Referral patterns between high- and low-volume centers and associations with uterine cancer treatment and survival: a population-based study of Medicare,

Referral patterns between high- and low-volume centers and associations with uterine cancer treatment and survival: a population-based study of Medicare,
Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment  Allan Hildesheim,

Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment  Allan Hildesheim,

Similar presentations

Ads by Google